Clinical Trials
2 trialsNCT02203513 2022-09-10
A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00321633 2013-08-26
Carboplatin or Docetaxel in Treating Women With Metastatic Genetic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed